Contains A Growth Factor Or Growth Regulator Patents (Class 435/405)
  • Publication number: 20040235166
    Abstract: The present invention encompasses methods and compositions for enhancing the growth of adult marrow stromal cells.
    Type: Application
    Filed: May 21, 2003
    Publication date: November 25, 2004
    Inventors: Darwin Prockop, Ichiro Sekiya, Carl Gregory, Jeffrey Spees, Jason Smith, Radhika Pochampally
  • Patent number: 6821780
    Abstract: A complex nutrient medium containing compounds that are biocompatible, biomimetic and bioavailable in the skin, but no biological extract of animal or cellular origin, for preparing a topical composition. Said complex nutrient medium has a suitable composition enabling viable in vitro culture of a human epidermal keratinocyte inoculum, with at least one clonal proliferation thereof during the first stage, and without the use of a live nutritive layer. The composition may be used as the active principle, particularly in a cosmetic preparation or a galenic base, and as a carrier capable of potentiating the activity of specific active principles.
    Type: Grant
    Filed: July 25, 1997
    Date of Patent: November 23, 2004
    Inventors: Jean-Noel Thorel, Hugues Gatto
  • Publication number: 20040185561
    Abstract: Provided are APF plant extracts, APF plant extract cell culture media supplements, APF plant extract cell culture media, and APF plant extract cell culture media kits for the support of primary culture and cultivation of normal cells.
    Type: Application
    Filed: March 18, 2003
    Publication date: September 23, 2004
    Applicant: Cascade Biologics, Inc.
    Inventor: Paul Weldon Cook
  • Patent number: 6767741
    Abstract: The present invention is directed generally to metal binding compounds which may be added to cell culture media to replace factors required for cultivation of the cells (e.g. transferrin) which are of animal or human origin. More specifically, the invention is directed to metal binding compounds or complexes thereof comprising one or more transition element cations (such as ferrous or ferric ions), which are added to cell and tissue culture medium compositions. The metal binding compounds may be added to the media alone or may be first complexed with a transition metal ion. The invention is also directed to methods of use of such compositions, including, for example, methods for the cultivation of eukaryotic cells, particularly animal cells, in vitro. The invention also relates to compositions comprising such culture media and one or more cells, and to kits comprising one or more of the above-describcd compositions.
    Type: Grant
    Filed: August 28, 2000
    Date of Patent: July 27, 2004
    Assignee: Invitrogen Corporation
    Inventors: David A. Epstein, Paul J. Battista, Dale F. Gruber, David A. Judd
  • Patent number: 6761883
    Abstract: A substantially enriched mammalian hematopoietic cell subpopulation is provided, which is characterized by progenitor cell activity for myeloid lineages, but lacking the potential to differentiate into lymphoid lineages. This population is further divided into specific myeloid progenitor subsets, including a common myeloid progenitor cells (CMP), megakaryocyte/erythroid progenitor cells (MEP) and granulocyte/monocyte lineage progenitor (GMP). Methods are provided for the isolation and culture of these subpopulations. The CMP population gives rise to all myeloid lineages, and can give rise to the two additional and isolatable progenitor populations that are exclusively committed to either the erythroid/megakaryocytic or myelomonocytic lineages. The cell enrichment methods employ reagents that specifically recognize Thy-1; and IL-7R&agr;, in conjunction with other markers expressed on lineage committed cells.
    Type: Grant
    Filed: September 17, 2001
    Date of Patent: July 13, 2004
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Irving L. Weissman, David Jeffrey Traver, Koichi Akashi, Markus Gabriel Manz, Toshihiro Miyamoto
  • Patent number: 6737270
    Abstract: A method is provided for long term culture of proliferating hepatocytes that retain hepatic function to produce a hepatic cell culture. Hepatocytes and nonparenchymal cells are co-cultured ex vivo on a matrix coated with a molecule that promotes cell adhesion, proliferation or survival, in the presence of growth factors, resulting in a long-term culture of proliferating hepatocytes that retain hepatic function. The co-culturing method results in the formation of matrix/hepatic cell clusters that may be mixed with a second structured or scaffold matrix that provides a three-dimensional structural support to form structures analogous to liver tissue counterparts. The method can be used to form bio-articial livers through which a subjects blood is perfused.
    Type: Grant
    Filed: December 7, 1999
    Date of Patent: May 18, 2004
    Assignee: University of Pittsburgh of the Commonwealth System of Higher Education
    Inventors: George Michalopoulos, William C. Bowen
  • Patent number: 6737051
    Abstract: The invention relates to a cell composition containing macrophages, presenting anti-infectious and hematopoietic properties. More particularly, the invention relates to a cell composition containing macrophages, myeloid cells and progenitors; said cell compositions are useful for the restoration of hematopoiesis in an aplasic patient and/or the protection of patients against infectious diseases or against residual tumors.
    Type: Grant
    Filed: November 27, 2001
    Date of Patent: May 18, 2004
    Assignees: I.D.M. Immuno-Designed Molecules, Centre Hospitalier Universitaire de Montpellier
    Inventors: Bernard Klein, Zhao Yang Lu, Jacques Bartholeyns
  • Patent number: 6733746
    Abstract: The present invention provides a serum-free supplement which supports the growth of hematopoietic cells in culture. Also provided are a medium comprising a basal medium supplemented with the serum-free supplement of the present invention. The present invention also provides methods for culturing and for differentiating hematopoietic cells.
    Type: Grant
    Filed: January 31, 1997
    Date of Patent: May 11, 2004
    Assignee: Invitrogen Corporation
    Inventors: John P. Daley, Barbara M. Dadey, William C. Biddle, Michelle G. Wysocki
  • Patent number: 6709864
    Abstract: A composition which comprises human mesenchymal stem cells which have the potential to differentiate into cells of more than one connective tissue type and a composition which induces cells from the mesenchymal stem cell population to differentiate into the adipogenic lineage, and a process for inducing such differentiation. The composition for inducing such differentiation comprises a glucocorticoid, a compound which stimulates cAMP production or inhibits cAMP degradation (such as a phosphodiesterase inhibitor), and/or a compound which upregulates peroxisome proliferator activated receptor &ggr; (PPAR &ggr;) expression and/or increases its binding affinity to its DNA binding site. The process can further include isolating the adipocytes from remaining hMSCs.
    Type: Grant
    Filed: March 28, 2000
    Date of Patent: March 23, 2004
    Assignee: Osiris Therapeutics, Inc.
    Inventors: Mark F. Pittenger, Stephen C. Beck
  • Patent number: 6692961
    Abstract: The present invention provides cell culture media formulations which support the in vitro cultivation of animal epithelial cells. The media comprise at least one fibroblast growth factor (FGF) and at least one agent that induces increased intracellular cAMP levels, and optionally comprise ascorbic acid. The present invention also provides methods of cultivating animal epithelial cells in vitro using these cell culture media formulations, kits comprising the media, cell culture compositions comprising the culture media and an animal epithelial cell, and compositions that may be used as replacements for organ or gland extracts in animal cell culture media.
    Type: Grant
    Filed: October 26, 2000
    Date of Patent: February 17, 2004
    Assignee: Invitrogen Corporation
    Inventors: David A. Judd, Paul J. Battista
  • Patent number: 6670146
    Abstract: Methods for increasing yields of regulatory T cells, useful, e.g., in transplantation contexts. Use of antigen presenting cells and anti-CD28 are also described.
    Type: Grant
    Filed: October 3, 2001
    Date of Patent: December 30, 2003
    Assignee: Schering Corporation
    Inventors: Franck J. Barrat, Pieter Andre Boonstra, Huub Savelkoul, Rene de Waal Malefyt, Anne O'Garra
  • Patent number: 6670180
    Abstract: A chemically defined mammalian cell culture medium is provided that supports maintenance and long term clonal growth of mammalian hepatocytes and other cells.
    Type: Grant
    Filed: February 12, 2002
    Date of Patent: December 30, 2003
    Assignee: University of Pittsburgh
    Inventor: Geoffrey D. Block
  • Patent number: 6627440
    Abstract: Disclosed is a cell culture medium including recombinant human alpha-fetoprotein or a cell-stimulating fragment or analog thereof.
    Type: Grant
    Filed: November 6, 1998
    Date of Patent: September 30, 2003
    Assignee: Martinex R & D Inc.
    Inventor: Robert A. Murgita
  • Patent number: 6617161
    Abstract: A chemically defined-serum free growth medium for the in vitro and ex vivo of cells and cell lines. The medium consists of about a one to one ratio (v/v) of two basal growth media containing &agr;-ketoglutarate, insulin, transferrin, selenium, bovine serum albumin, linoleic acid, ceruloplasmin, cholesterol, phosphatidyl-ethanolamine, &agr;-tocopherol acid succinate, reduced glutathione, taurine, triiodothyronine, hydrocortisone, parathyroid hormone, L-ascorbic acid 2-sulfate, &bgr;-glycerophosphate, PDGF, EGF and FGF. Chondrocytes, when cultured in this medium in the presence of a cartilage derived morphogenetic protein or bone morphogenetic protein, retain their cartilaginous phenotype.
    Type: Grant
    Filed: May 9, 2001
    Date of Patent: September 9, 2003
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Frank P. Luyten, Ludwig Erlacher
  • Patent number: 6610543
    Abstract: The invention relates to compositions for in vitro fertilization, or for the in vitro culture of follicles, male germinal cells or embryos, said compositions comprising at least two growth factors in association with a compound of the family of corticoids involved in energetic production in mammals. The invention also relates to the culture media obtained with these compositions, these latter being preferably in the form of a lyophilizate. The invention also has for its object processes for the in vitro fertilization and processes for maturation of follicles, of male germinal cells, or embryos using such culture media, as well as kits for the practice of these processes and comprising a lyophilizate as mentioned above and an aqueous solution, if desired commercial, containing other constituents of said culture medium.
    Type: Grant
    Filed: July 24, 2001
    Date of Patent: August 26, 2003
    Assignee: Laboratoire C.C.D.
    Inventors: Patrick Choay, Serge Weinman
  • Publication number: 20030157473
    Abstract: Disclosed are compositions for mammalian, avian or piscian reproductive cells and methods for the collection, holding, processing, in vitro fertilization, sexing culturing, or storing (including long-term cryopreservation) of mammalian, avian, or piscian reproductive sperm cells. The compositions comprise a suitable reproductive cell media and a transforming growth factor, an insulin-like growth factor, or zinc, and, optionally, inositol, transferrin, or fructose, or combinations thereof.
    Type: Application
    Filed: February 21, 2002
    Publication date: August 21, 2003
    Applicant: Minitube of America
    Inventors: Kevin J. Rozeboom, Mark E. Wilson
  • Publication number: 20030148516
    Abstract: Ligands for flt3 receptors capable of transducing self-renewal signals to regulate the growth, proliferation or differentiation of progenitor cells and stem cells are disclosed. The invention is directed to flt3-L as an isolated protein, the DNA encoding the flt3-L, host cells transfected with cDNAs encoding flt3-L, compositions comprising flt3-L, methods of improving gene transfer to a mammal using flt3-L, and methods of improving transplantations using flt3-L. Flt3 -L finds use in treating patients with anemia, AIDS and various cancers.
    Type: Application
    Filed: December 19, 1997
    Publication date: August 7, 2003
    Inventors: STEWART D. LYMAN, M. PATRICIA BECKMANN
  • Patent number: 6599740
    Abstract: A process of using a fish plasma component as a nutrient medium component for tissue culture includes obtaining blood from a fish, separating plasma from the blood, and extracting one or more specific components of the plasma. The tissue is cultured using the extracted plasma components, and none of any remainder of the plasma, in a nutrient medium. The tissue cultured using the extracted plasma component is other than fish tissue, such as mammalian tissue or insect tissue.
    Type: Grant
    Filed: July 18, 2001
    Date of Patent: July 29, 2003
    Assignee: Sea Run Holdings, Inc.
    Inventors: Evelyn A. Sawyer, Paul A. Janmey, Lisa A. Flanagan
  • Patent number: 6593140
    Abstract: An animal cell culture medium is described which contains 2-hydroxy-2,4,6-cycloheptatrien-1-one or a derivative thereof to support the growth of animal cells, particularly in agitated cell culture at low iron concentrations.
    Type: Grant
    Filed: April 7, 1995
    Date of Patent: July 15, 2003
    Assignee: Lonza Group, AG
    Inventor: Raymond Paul Field
  • Patent number: 6585969
    Abstract: Cultures of keratinocyte cells are provided which are free from nonautologous fibroblasts and organ extracts, and which have a high speed of cell amplification for a minimum seeding density. The cultures can be cryopreserved in a buffered isotonic medium containing serum and a cryoprotectant. The cultures are produced by a process that does not involve the use of a feeder layer and organ extracts. A culture medium which can be used contains Medium 199, serum, epidermal growth factor, cholera toxin and/or hydrocortisone, and optionally insulin. A substance for wound healing and for cosmetic applications is derived from cultured human keratinocytes. A non-viable total keratinocyte lysate for use in promoting wound healing is produced by growing keratinocyte cells on a support, detaching the cells from the support, and lysing the detached cells to obtain the lysate which may be frozen and lyophilized.
    Type: Grant
    Filed: February 1, 1999
    Date of Patent: July 1, 2003
    Assignee: N. V. Innogenetics S.A.
    Inventor: Hans Van Bossuyt
  • Patent number: 6582960
    Abstract: The present invention provides an improved method for expanding cells for use in tissue engineering. In particular the method provides specific biochemical factors to supplement cell culture medium during the expansion process in order to reproduce events occurring during embryonic development with the goal of regenerating tissue equivalents that resemble natural tissues both structurally and functionally. These specific biochemical factors improve proliferation of the cells and are capable of de-differentiation mature cells isolated from tissue so that the differentiation potential of the cells is preserved. The bioactive molecules also maintain the responsiveness of the cells to other bioactive molecules. Specifically, the invention provides methods for expanding chondrocytes in the presence of fibroblast growth factor 2 for use in regeneration of cartilage tissue.
    Type: Grant
    Filed: September 17, 1999
    Date of Patent: June 24, 2003
    Assignee: Massachusetts Institute of Technology
    Inventors: Ivan Martin, Lisa E. Freed, Robert Langer, Gordana Vunjak-Novakovic
  • Patent number: 6562620
    Abstract: The present invention relates to a medium for promoting the survival of islet cells, which comprises one or more growth factors in combination with FK506 in amounts having an anti-apoptotic effect on islet cells in a physiologically acceptable culture medium.
    Type: Grant
    Filed: May 6, 2002
    Date of Patent: May 13, 2003
    Assignee: McGill University
    Inventors: Lawrence Rosenberg, Dusica Maysinger
  • Patent number: 6558941
    Abstract: Nanoemulsions are prepared containing oily droplets of a diameter of less than 100 nm in an aqueous phase. The oily droplets contain a lipophilic substance, and have on their surface an amphoteric emulsifier in an amount of preferably 0.65 to 0.75 parts by weight amphoteric emulsifier for one part by weight of oily component forming the droplets. The oily component of the droplets is preferably a triglyceride containing oleic acid and/or linoleic acid. The nanoemulsions, which may be sterile, are used for delivering into cells the lipophilic substance contained by the oily droplets. This delivery can be used to biotransform the lipophilic substance, promote cell differentiation, growth or biosynthesis of a desired substance, or to test for toxicity of the lipophilic substance.
    Type: Grant
    Filed: June 29, 2001
    Date of Patent: May 6, 2003
    Assignee: Mibelle AG Cosmetics
    Inventors: Fred Zuelli, Franz Suter
  • Patent number: 6541249
    Abstract: A method for the culture of hematopoietic cells and/or production of human cytokines using immortalized human stromal cell lines is provided. These immortalized stromal cell lines condition media such that the ability of the hematopoietic stem cells to self-replicate and/or differentiate is maintained by the media or the ability of the committed progenitors to expand and/or differentiate is maintained by the media. Further provided are irradiated and non-irradiated immortalized human stromal cells that synthesize cytokines, such as, IL-7, IL-8, IL-11, FLT3L, SCF, LIF, M-CSF, TGF-beta 1, GM-CSF, MIP-1alpha, G-CSF, and MCP-1.
    Type: Grant
    Filed: December 21, 2000
    Date of Patent: April 1, 2003
    Assignee: Human Genome Sciences, Inc.
    Inventors: Ruth E. Wager, Maria Ourmanova
  • Patent number: 6541256
    Abstract: A human cell growth medium formulation for culturing human cells of neural crest origin, most preferably corneal endothelial cells, or for accelerating the growth and proliferation of human cells of neural crest origin is disclosed. The formulation for the nutrient medium of the invention includes nerve growth factor, preferably at a concentration of 1-100 ng/ml and most preferably 20 ng/ml. The growth medium formulation preferably also includes epidermal growth factor (preferably at a concentration of 1-200 ng/ml and most preferably 5 ng/ml).
    Type: Grant
    Filed: September 14, 2001
    Date of Patent: April 1, 2003
    Assignee: The Schepens Eye Research Institute, Inc.
    Inventors: Ko-Hua Chen, Nancy C. Joyce
  • Patent number: 6537812
    Abstract: The method for obtaining and expanding TcR&ggr;&dgr;+ T cells in culture is described. The method involves: 1) culturing cells from a sample containing TcR&ggr;&dgr;+ T cells or precursors thereof in a first culture medium comprising a T cell mitogen and at least two cytokines and 2) culturing the cells obtained in step 1) in a second culture medium comprising at least two cytolines. Preferably, the method comprises 1) culturing the cells in a first culture medium comprising (a) a T cell mitogen, (b) interleukin-2 and (c) interleukin-4, and 2) culturing the cells obtained in step 1) in a second culture medium comprising (i) interleukin-2 and (ii) interleukin-4 to obtain TcR&ggr;&dgr;+ T cells. The TcR&ggr;&dgr;+ T cells obtained by the method can be used in a variety of experimental, therapeutic and commercial applications.
    Type: Grant
    Filed: July 30, 2001
    Date of Patent: March 25, 2003
    Assignee: Hemosol Inc.
    Inventors: David Nicholson Bell, Danna Lynn Skea, Phyllis Robin Hedge
  • Publication number: 20030049840
    Abstract: Disclosed is a universally-adaptable cell preconditioning and storage medium that can be used for the effective cryopreservation of cells at temperatures less than 4° C. The aqueous medium contains adenosine, a calcium channel blocker, and a nutrient-rich matrix that has a sufficient amount of cell metabolites to sustain the metabolic needs of the harvested cells while incubating the cells for a period of at least 10 minutes, without producing detectable levels of lactate or substantially depleting the metabolic substrates of the cell.
    Type: Application
    Filed: September 20, 2002
    Publication date: March 13, 2003
    Inventors: Achilles A. Demetriou, Andreas Kamlot, Jacek Rozga
  • Patent number: 6500668
    Abstract: A culture medium for avian embryonic cells and an avian cell culture medium is disclosed. The culture medium is characterized in that it has elements complementary to avian embryonic cells. The complementary elements are cytokines, fibroblast growth factors, insulin-like growth factors or stem cell growth factors. The medium is substantially free of active retinoic acid. A method for culturing avian embryonic cells, and the resulting products, are also disclosed.
    Type: Grant
    Filed: September 1, 1999
    Date of Patent: December 31, 2002
    Inventors: Jacques Samarut, Bertrand Pain
  • Patent number: 6495522
    Abstract: The present invention is directed to novel substituted &agr;-hydroxy acid thereof, represented by the general Formula I: where R1-R5, X and Z are defined herein. The present invention also relates to the discovery that compounds having Formula I are potent inhibitors of caspases and apoptotic cell death. Therefore, the inhibitors of this invention can retard or block cell death in a variety of clinical conditions in which the loss of cells, tissues or entire organs occurs.
    Type: Grant
    Filed: August 28, 2000
    Date of Patent: December 17, 2002
    Assignee: Cytovia, Inc.
    Inventors: Yan Wang, Sui Xiong Cai, Eckard Weber, Gordon B. Mills, Douglas R. Green, Lufeng Guan
  • Patent number: 6458589
    Abstract: It has been discovered that when pluripotent stem cells are cultured in the presence of a hepatocyte differentiation agent, a population of cells is derived that has a remarkably high proportion of cells with phenotypic characteristics of liver cells. In one example, human embryonic stem cells are allowed to form embryoid bodies, and then combined with the differentiation agent n-butyrate, optionally supplemented with maturation factors. In another example, n-butyrate is added to human embryonic stem cells in feeder-free culture. Either way, a remarkably uniform cell population is obtained, which is predominated by cells with morphological features of hepatocytes, expressing surface markers characteristic of hepatocytes, and having enzymatic and biosynthetic activity important for liver function.
    Type: Grant
    Filed: November 20, 2000
    Date of Patent: October 1, 2002
    Assignee: Geron Corporation
    Inventors: Lakshmi Rambhatla, Melissa K. Carpenter
  • Patent number: 6458585
    Abstract: A method for producing human dendritic cells for therapeutic purposes which allows culture-deriving dendritic cells using no cytokines, or reduced cytokines. The method involves culturing mononuclear cells from blood or bone marrow in a medium containing at least one agent such as a calcium ionophore, e.g. A23187, theophylline, protaglandin E1, dibutyryl cyclic AMP, Vitamin D3, Vitamin E, retinoic acid, or a fatty acid. The culture is maintained for a sufficient time, typically 4-14 days, to produce a culture enriched for dendritic cells, as evidenced by at least about 2.5% of total cells exhibiting dendritic cell processes, or a dendritic dell antigen such as CD80, CD86, or CD1a. Also provided is a method to produce antigen-specific human T-cells by pulsing the dendritic cells obtained by the method of the invention with an antigen such as a viral, tumor, bacterial, or cell surface antigen, and then co-culturing T-cells with the antigen-pulsed dendritic cells.
    Type: Grant
    Filed: July 31, 1997
    Date of Patent: October 1, 2002
    Assignee: Nexell Therapeutics Inc.
    Inventors: Mona Vachula, Dennis E. Van Epps, Mortimer T. Alzona, Frederick M. Aono
  • Patent number: 6451601
    Abstract: The invention provides methods and compositions for expanding cells that are not abundant or are difficult to obtain in pure form in culture, are in short supply (e.g., human cells), or have brief lifetimes in culture, using fusion polypeptide. The fusion polypeptide has a first region containing a translocation carrier moiety having the function of a transport polypeptide amino acid sequence from, e.g., herpesviral VP22, HIV TAT, Antp HD, Arg repeats, or a cationic polymer, or from homologues or fragments thereof, and a second region with a polypeptide having cell immortalization activity, a polypeptide having telomerase-specific activity, or a polypeptide having telomerase gene activation activity. The resulting cells of the invention are suitable for use in cell therapy.
    Type: Grant
    Filed: March 29, 2001
    Date of Patent: September 17, 2002
    Assignee: Modex Therapeutiques, S.A.
    Inventors: Edward E. Baetge, Shou Wong, Philippe Dupraz, Bernard Thorens
  • Patent number: 6440740
    Abstract: The present invention provides a novel material for activating epidermal cell multiplication on which not only effective adhesion and multiplication of human and mammalian epidermal cells is accomplished also intercellular adhesion is promoted to form a plain cellular layer. The present invention provides a material for activating epidermal cell multiplication which contains silk fibroin of &agr;-type or &agr;-helix X-ray diffraction pattern as a principal constituent. The present material fulfills the principal requirements for activating epidermal cells of greatly improved cellular adhesion rate, multiplication, intercellular adhesion and growth of cell layers.
    Type: Grant
    Filed: July 16, 1999
    Date of Patent: August 27, 2002
    Assignees: Japan as represented by Director General of National Institute of Sericultural and Entomological Science, Ministry of Agriculture, Forestry and Fisheries
    Inventors: Kozo Tsubouchi, Hiromi Yamada, Yoko Takasu
  • Patent number: 6436411
    Abstract: Treatment of tumors, including their metastases, is described. Retrieved cytokines and other molecules from the growth medium of human monocytes stimulated ex vivo with gamma globulin, or other immune stimulators are employed for cancer therapy.
    Type: Grant
    Filed: October 23, 2000
    Date of Patent: August 20, 2002
    Assignee: The Center for the Improvement of Human Functioning, Int'l., Inc.
    Inventors: Neil H. Riordan, Hugh D. Riordan
  • Patent number: 6436704
    Abstract: The invention discloses a substantially pure population of human pancreatic progenitor cells and methods of isolating and culturing the pancreatic progenitor cells. By carefully manipulating the microenvironment of the pancreatic progenitor cells, multiple passages are attainable wherein the pancreatic progenitor cells do not senesce and furthermore, are capable of becoming functional exocrine or endocrine cells. In addition, several methods of use of human pancreatic progenitor cells are disclosed herein.
    Type: Grant
    Filed: April 10, 2000
    Date of Patent: August 20, 2002
    Assignee: Raven Biotechnologies, Inc.
    Inventors: Penelope E. Roberts, Jennie Powell Mather
  • Publication number: 20020094331
    Abstract: The present invention relates to an enzymatic composition capable of killing or inhibiting microbial cells or micro-organisms, e.g. in laundry, on hard surfaces, in water systems, on skin, on teeth or on mucous membranes. The present invention also relates to the use of said enzymatic composition for preserving food products, cosmetics, paints, coatings, etc.
    Type: Application
    Filed: November 9, 1999
    Publication date: July 18, 2002
    Inventors: CHARLOTTE JOHANSEN, HEINZ-JOSEF DEUSSEN
  • Patent number: 6416999
    Abstract: This invention discloses a substantially pure population of human Müllerian duct-derived epithelial cells and methods of isolating and culturing the Müllerian duct-derived epithelial cells. By carefully manipulating the microenvironment in which the Müllerian duct-derived epithelial cells are grown, multiple passages are attainable wherein the Müillerian duct-derived epithelial cells are capable of becoming uterine, cervical, vaginal, and oviductal cells. In addition, several uses of human Müllerian duct-derived epithelial cells and cells differentiating therefrom are disclosed herein.
    Type: Grant
    Filed: April 7, 2000
    Date of Patent: July 9, 2002
    Assignee: Raven Biotechnologies, Inc.
    Inventors: Rong-hao Li, Jennie Powell Mather
  • Patent number: 6413772
    Abstract: A chemically defined mammalian cell culture medium is provided that supports maintenance and long term clonal growth of mammalian hepatocytes and other cells.
    Type: Grant
    Filed: March 12, 1999
    Date of Patent: July 2, 2002
    Assignee: University of Pittsburgh
    Inventor: Geoffrey D. Block
  • Publication number: 20020081729
    Abstract: The materials and methods are particularly useful in media for cell culturing but have other applications as well, such as in tissue engineering. The materials comprise at least one growth factor or other cell growth facilitating substance contained within a polymeric structure which can incorporate the substance and allow controlled release of the substance. Alginate materials are particularly useful as the polymeric structure. Another feature described herein is the above-described materials provided in a lyophilized (freeze-dried) form which greatly enhances their storage life.
    Type: Application
    Filed: March 26, 1999
    Publication date: June 27, 2002
    Inventors: MARTIN C. PETERS, JONATHON A. ROWLEY, DAVID J. MOONEY
  • Publication number: 20020076747
    Abstract: The present invention provides a serum-free supplement which supports the growth of embryonic stem cells in culture. Also provided are a medium comprising a basal medium supplemented with the serum-free supplement of the present invention. The present invention also provides methods for culturing and isolating embryonic stems cells, methods for producing a transgenic animal, and methods for expressing recombinant protein in embryonic stem cells and transgenic animals.
    Type: Application
    Filed: September 7, 1999
    Publication date: June 20, 2002
    Inventors: PAUL J. PRICE, MINDY D. GOLDSBOROUGH, MARY LYNN TILKINS
  • Patent number: 6399381
    Abstract: Human epithelial colon immortalized cell line, which does not express tumour markers, which expresses metabolic markers specific for the non-immortalized human epithelial cells and metabolic differentiation markers specific for the non-immortalized epithelial cells of the human colon, and which is capable of adhering in vitro to the strain of lactic acid bacterium CNCM-1225. Serum-free culture medium characterized in that it comprises trace elements, vitamins consisting of vitamin C and retinoic acid, and hormones consisting of triiodothyronine, dexamethasone, hydrocortisone, bovine pituary gland extract, insulin, EGF and transferrin. Process for the immortalization of epithelial cells of the human colon, in which a culture of primary epithelial cells derived from the human colon is prepared, the culture is infected with a recombinant virus, the immortalized cells are cultured in the serum-free culture medium according to the invention.
    Type: Grant
    Filed: June 14, 2000
    Date of Patent: June 4, 2002
    Assignee: Nestac S.A.
    Inventors: Stéphanie Blum, Andrea Pfeifer, Yvonne Tromvoukis
  • Patent number: 6372210
    Abstract: A serum-free medium which supports the proliferation and differentiation of CD34+ cells purified from normal bone marrow, peripheral blood of patients treated with cytokines, and umbilical cord blood is described. The recipe for the formulation is given, which provides a medium suitable for the proliferation and differentiation of CD34+ cells for use in human therapeutic protocols. The cells CD34+ cultured in a the medium of the present invention are used in a method for repopulating human host bone marrow.
    Type: Grant
    Filed: February 9, 2001
    Date of Patent: April 16, 2002
    Assignee: Quality Biological, Inc.
    Inventor: Ronald L. Brown
  • Patent number: 6361998
    Abstract: The present invention describes a serum-free medium that promotes the growth and differentiation of erythroid cells, cells that are highly transducible by a non-viral method and genes which increase the growth of erythroid cells and decrease their dependency on Epo. This invention can be used in the expansion of hematopoietic stem cells to produce cultures of erythroid cells as a source of erythroid-specific proteins such as hemoglobin. Hematopoietic stem cells are cultured ex vivo in a serum-free culture medium with the addition of IL-3, SCF and EPO. Cells transfected with the gene described in the present invention can be cultured in the serum-free culture medium with decreased dependency on Epo and other cytokines, thereby reducing the cost of the production of hemoglobin.
    Type: Grant
    Filed: June 25, 1999
    Date of Patent: March 26, 2002
    Assignee: Hemosol Inc.
    Inventors: David N. Bell, Kathryn Emma Matthews, Susan G. Mueller
  • Patent number: 6355237
    Abstract: The present invention relates to methods for using various forms of a novel receptor expressed by hematopoietic and endothelial cells. An additional variant form of this receptor has been detected in brain cells and shown to bind to the obese gene product, leptin. Therefore, leptin may be used to stimulate the growth and development of receptor-positive hematopoietic and endothelial cells in vitro and in vivo. In addition, this receptor is selectively expressed in hematopoietic progenitor cells with long-term repopulating potential. Thus, agents that specifically bind to this receptor may be used to identify and isolate progenitor cells for a variety of clinical applications.
    Type: Grant
    Filed: March 20, 1996
    Date of Patent: March 12, 2002
    Assignee: Progenitor, Inc.
    Inventors: H. Ralph Snodgrass, Joseph Cioffi, Thomas Joel Zupancic, Alan Wayne Shafer
  • Publication number: 20020028509
    Abstract: The invention relates to compositions for the in vitro fertilization, or for the in vitro culture of follicles, male germinal cells or embryos, said compositions comprising at least two growth factors in association with a compound of the family of corticoids involved in energetic production in mammals. The invention also relates to the culture media obtained with these compositions, these latter being preferably in the form of a lyophilizate.
    Type: Application
    Filed: July 24, 2001
    Publication date: March 7, 2002
    Inventors: Patrick Choay, Serge Weinman
  • Publication number: 20020001826
    Abstract: A method for the culture of hematopoietic cells and/or production of human cytokines using immortalized human stromal cell lines is provided. These immortalized stromal cell lines condition media such that the ability of the hematopoietic stem cells to self-replicate and/or differentiate is maintained by the media or the ability of the committed progenitors to expand and/or differentiate is maintained by the media. Further provided are irradiated and non-irradiated immortalized human stromal cells that synthesize cytokines, such as, IL-7, IL-8, IL-11, FLT3L, SCF, LIF, M-CSF, TGF-beta 1, GM-CSF, MIP-1alpha, G-CSF, and MCP-1.
    Type: Application
    Filed: December 21, 2000
    Publication date: January 3, 2002
    Inventors: Ruth E. Wager, Maria Ourmanova
  • Patent number: 6333193
    Abstract: Provided are a cell growth accelerator containing a polyphosphoric acid and a cell growth method in which cells are grown by adding the cell growth accelerator to a medium for cells of animals and plants or by using a glass or plastic cell cultivator containing or coated with the cell growth accelerator. When substances are produced in vitro using culture cells, the cell culture and the cell growth acceleration are conducted at low cost safely and efficiently by adding the cell growth accelerator containing the polyphosphoric acid to the medium for cells of animals and plants or by using the cell cultivator containing or coated with the cell growth accelerator.
    Type: Grant
    Filed: August 27, 1999
    Date of Patent: December 25, 2001
    Assignee: Nipro Corporation
    Inventor: Toshikazu Shiba
  • Publication number: 20010051148
    Abstract: The present invention relates to a method for preconditioning healthy donor's myoblasts in vitro before transplantation thereof in compatible patients suffering of recessive myopathies, particularly of muscular dystrophy. This in vitro preconditioning improves the success of the transplantation while not requiring an in vivo preconditioning of the patient's muscle by irradiation or by administering muscular toxin. The invention further relates to compositions comprising such preconditioned myoblasts.
    Type: Application
    Filed: November 10, 1998
    Publication date: December 13, 2001
    Inventor: JACQUES P. TREMBLAY
  • Patent number: 6326194
    Abstract: Growth of keratinocytes is provided by subjecting a basal medium, insulin, pituitary compound and keratinocytes to cell growth conditions. Cell growth can be provided in the absence of exogenous epidermal growth factor. A conditioned medium results after the keratinocytes are subjected to cell growth conditions, treated keratinocytes are provided, and the treated keratinocytes are subjected to cell growth conditions in a basal medium. The conditioned medium contains autocrine factor. The conditioned medium then is contacted with further keratinocytes to provide a cell growth mixture. The cell growth mixture is subjected to incubation in order to provide replicative DNA synthesis and hence cell proliferation. Cells so provided can be used for dermatological research, toxicological testing and skin grafts.
    Type: Grant
    Filed: March 11, 1993
    Date of Patent: December 4, 2001
    Inventors: Geoffrey Michael Curtin, David Wayne Bombick, David James Doolittle
  • Patent number: 6323025
    Abstract: Compounds termed “vitaletheine modulators” which include beta-alanyl-taurine and carbobenzoxy beta-alanyl-taurine are synthesized and added to culture media for in vitro culture of cells such as mammalian or plant cells. The compounds support cell vitality, and provide increased cellular life span, increased cellular bioproductivity, improved cellular function, and adaption of resistant cells to culturing. The compounds further delay senescence, optimize growth and maturation, and increase population doublings.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: November 27, 2001
    Assignee: University of New Mexico
    Inventors: Galen D. Knight, Terence J. Scallen